Evaluation of gatifloxacin pharmacokinetics and pharmacodynamics in severely ill adults in a medical Intensive Care Unit

International Journal of Antimicrobial Agents

Volumn 29, Issue 6, 2007, Pages 715-723

  Fish, Douglas N ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Critically ill; Gatifloxacin; Intensive Care Unit; Pharmacodynamics; Pharmacokinetics

Indexed keywords

GATIFLOXACIN; PARACETAMOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACTERIAL PERITONITIS; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG HALF LIFE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTENSIVE CARE UNIT; KIDNEY CONCENTRATING CAPACITY; KIDNEY FUNCTION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NAUSEA; PATHOGENESIS; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; URINARY TRACT INFECTION;

ADULT; AGED; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CASE-CONTROL STUDIES; CREATININE; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROQUINOLONES; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 34248171208     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.02.006     Document Type: Article

References (15)

1. Power B.M., Forbes A.M., van Heerden P.V., and Ilett K.F. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet 34 (1998) 25-56
2. Rebuck J.A., Abraham E., and Fish D.N. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy 22 (2002) 1216-1225
3. Forrest A., Nix D.E., Ballow C.H., Goss T.F., Birmingham M.C., and Schentag J.J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37 (1993) 1073-1081
4. Cockroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
5. Overholser B.R., Kays M.B., and Sowinski K.M. Determination of gatifloxacin in human serum and urine by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 798 (2003) 167-173
6. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26 (1998) 1-10
7. Drusano G.L., Preston S.L., Fowler C., Corrado M., Weisinger B., and Kahn J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 189 (2004) 1590-1597
8. Preston S.L., Drusano G.L., Berman A.L., et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279 (1998) 125-129
9. Wright D.H., Brown G.H., Peterson M.L., and Rotschafer J.C. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 46 (2000) 669-683
10. Zelenitsky S.A., Harding G.K., Sun S., Ubhi K., and Ariano R.E. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother 52 (2003) 668-674
11. ® (gatifloxacin) product package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2006.
12. Gajjar D.A., LaCreta F.P., Uderman H.D., et al. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men. Pharmacotherapy 20 (2000) 49S-58S
13. Jones R.N., Rubino C.M., Bhavnani S.M., and Ambrose P.G. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob Agents Chemother 47 (2003) 292-296
14. LaCreta F.P., Kollia G.D., Duncan G., Behr D., and Grasela D.M. Age and gender effects on the pharmacokinetics of gatifloxacin. Pharmacotherapy 20 (2000) 67S-75S
15. Ambrose P.G., Bhavnani S., Cirincione B.B., Piedmont M., and Grasela T.H. Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. J Antimicrob Chemother 52 (2003) 435-440